Transplantation & Cellular Therapy

The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic hematopoietic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, CAR natural killer cell therapies, and genetically modified T-cell receptors, is also expanding to offer more patients curative options.

Advertisement
Advertisement
Nichole TuckerTransplantation & Cellular Therapy | December 19, 2024
Approval was granted by the FDA on the basis of findings from the phase 3 MSB-GVHD001 clinical trial.
Andrew MorenoT-Cell Lymphoma | December 10, 2024
Limitations on benefits from immunotherapy in this setting increase clinical interest in this CAR T-cell therapy approach.
Andrew MorenoMeeting News | December 9, 2024
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Andrew MorenoMeeting News | December 9, 2024
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
Andrew MorenoMeeting News | December 9, 2024
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Melissa BadamoTransplantation & Cellular Therapy | December 9, 2024
Odronextamab monotherapy showed promising efficacy in patients with high-risk, grade 1-3a follicular lymphoma.
Patrick DalyTransplantation & Cellular Therapy | December 7, 2024
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Patrick DalyTransplantation & Cellular Therapy | December 7, 2024
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Nichole TuckerTransplantation & Cellular Therapy | December 8, 2024
Upfront treatment with fixed-duration subcutaneous mosunetuzumab demonstrated a high complete response rate in FL and MZL.
Nichole TuckerTransplantation & Cellular Therapy | December 7, 2024
Phase 1 study results hint response durability for novel CAR-T agent, CAR22 in certain patients with large B-cell lymphoma.
Melissa BadamoTransplantation & Cellular Therapy | December 5, 2024
Molecular features typically associated with inferior outcomes did not significantly affect survival or CAR-T response.
Melissa BadamoTransplantation & Cellular Therapy | December 5, 2024
Liso-cel plus ibrutinib demonstrates substantial efficacy, deep remissions, and manageable safety.
Melissa BadamoTransplantation & Cellular Therapy | December 5, 2024
Although liso-cel has a higher total cost than mosunetuzumab, it provides increased survival and reduced time toxicity.
Melissa BadamoTransplantation & Cellular Therapy | December 5, 2024
Patients treated with tisa-cel, axi-cel, or liso-cel had an ORR of 65% and a one-month CR rate of 46%.
Andrew MorenoTransplantation & Cellular Therapy | October 24, 2024
A study has compared responses with anti-CD19 CAR-T therapy in MCL with and without active CNS involvement at infusion.
Andrew MorenoTransplantation & Cellular Therapy | October 24, 2024
An MAIC analysis of data from clinical trials identified differences in efficacy and safety between the two interventions.
Andrew MorenoTransplantation & Cellular Therapy | October 23, 2024
The authors found the complete response rate results to be promising and to warrant further clinical investigation.
Melissa BadamoTransplantation & Cellular Therapy | October 4, 2024
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
Melissa BadamoTransplantation & Cellular Therapy | October 24, 2024
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
Andrew MorenoTransplantation & Cellular Therapy | October 7, 2024
Encouraging efficacy and safety seen over 17 months in a phase II trial continued into the trial's 29-month follow-up period.
Andrew MorenoTransplantation & Cellular Therapy | October 7, 2024
In a retrospective study bendamustine compared favorably with the cyclophosphamide plus fludarabine lymphodepletion regimen.
Andrew MorenoTransplantation & Cellular Therapy | October 7, 2024
A first ever phase I/II trial tested escalating doses in patients with relapsed or refractory disease.
Andrew MorenoTransplantation & Cellular Therapy | July 17, 2024
Axi-cel produced sustained long-term responses in patients with follicular lymphoma and marginal zone lymphoma.
Andrew MorenoTransplantation & Cellular Therapy | July 18, 2024
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Patrick DalyFollicular Lymphoma | October 4, 2024
Treatment with liso-cel was effective and safe in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Manali Kamdar, MDTransplantation & Cellular Therapy | August 23, 2024
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Melissa BadamoAggressive B-Cell Lymphoma | June 3, 2024
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
Melissa BadamoFollicular Lymphoma | June 3, 2024
The median progression-free survival, duration of response, and overall survival were not reached.
Leah LawrenceTransplantation & Cellular Therapy | May 22, 2024
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
Magdi Elsallab, MD, PhDTransplantation & Cellular Therapy | April 17, 2024
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
Melissa BadamoTransplantation & Cellular Therapy | May 21, 2024
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
Sarah ValentineAcute Myeloid Leukemia | April 2, 2024
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Sarah ValentineAggressive B-Cell Lymphoma | March 26, 2024
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
Douglas Tremblay, MDMyelodysplastic Syndromes | March 15, 2024
The study also explored the role of this combination in transitioning patients to HSCT.
Melissa BadamoAcute Myeloid Leukemia | March 7, 2024
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
Cecilia BrownIndolent B-Cell Lymphoma | June 26, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 17, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Richard Newcomb, MDTransplantation & Cellular Therapy | February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
Melissa BadamoMyeloma | March 19, 2024
The study used public data from various online sources related to approved CAR-T therapies for MM.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Melissa BadamoPrint | February 8, 2024
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Patrick DalyPrint | February 7, 2024
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Patrick DalyTransplantation & Cellular Therapy | February 2, 2024
Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life.
Blood Cancer TalksBlood Cancer Talks | January 24, 2024
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Leah SherwoodTransplantation & Cellular Therapy | January 5, 2024
GVHD affects approximately 30,000 Americans, according to Dr. Michael Chancellor, Chief Medical Officer at Lipella.
Ajai Chari, MDTransplantation & Cellular Therapy | January 24, 2024
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Afaf Osman, MDAcute Myeloid Leukemia | March 5, 2024
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
Patrick DalyMyelofibrosis | October 12, 2023
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.